Elbasvir-Grazoprevir Zepatier
Glecaprevir-Pibrentasvir Mavyret
Ledipasvir-Sofosbuvir Harvoni
Ribavirin Copegus, Rebetol, Ribasphere
Sofosbuvir Sovaldi
Sofosbuvir-Velpatasvir Epclusa
Sofosbuvir-Velpatasvir-Voxilaprevir VoseviSelf-StudyEvaluation and Preparation for Hepatitis C Treatment
Evaluation and Preparation for Hepatitis C Treatment
You are just a few steps away from free CE credits!
Sign in or Register
A free account is required.
Study the Material
An entire Cc section, or just a few topics at a time.
Take the CE Quiz
5 questions covering the topics in each Cc section.
Claim CE Credit
Free CNE and Free CME available!
- Lesson 3 Overview
Addressing Structural Barriers to HCV Treatment - 0%Topic 1
BackgroundActivities- 0%Topic 2
The Path to HCV Cure: HCV Care ContinuumActivities- 0%Topic 3
HCV Testing: Access, Efficiency, and ReimbursementActivities- 0%Topic 4
Improving Services for Linkage-to-CareActivities- 0%Topic 5
Expanding Medical Provider CapacityActivities- 0%Topic 6
Expanding Settings for HCV Clinical Care and TreatmentAddressing Structural Barriers to HCV Treatment Overview
About this Lesson
Last Updated: April 20th, 2024CNE/CME Continuing Education
This lesson qualifies for:- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour and 1 CE contact hour (does NOT qualify for pharmacology CE for advanced practice nurses)
CNE and CME Origination: January 26th, 2022CNE and CME Review: April 29th, 2024CNE and CME Expiration: April 28th, 2027 (4th Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
1Quiz
Score 80%+2Give Feedback
Complete survey3Print CE Certificate
Obtain proof of CE4th Edition
This is a substantial revision of the original Lesson. The previous edition was titled Addressing Structural Barriers to HCV Treatment and available until April 29th, 2024.Learning Objectives
- State the key steps in HCV care continuum
- List major barriers to hepatitis C testing
- Describe approaches for improving linkage to hepatitis C care services
- Explain potential insurance and Medicaid restrictions that can limit access to HCV treatment
- Discuss strategies for expanding hepatitis C medical provider capacity
Lesson Contributors
Authors
Oluwaseun Falade-Nwulia, MBBS, MPHOluwaseun Falade-Nwulia, MBBS
Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of MedicineDisclosures:Grants to institution: Abbvie
Consulting fee: GileadThe relevant financial relationship was mitigated.H. Nina Kim, MD, MScH. Nina Kim, MD, MSc
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneReviewers
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneLesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Funded byCenters for Disease Control and Prevention Cooperative Agreement (CDC-RFA-PS21-2105)Created at University of WashingtonPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE provided byUniversity of Washington School of NursingCopyright © 2024 Hepatitis C OnlineSince you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhcvc-master-9e0a1e65-2024-12-09-232944 - 0%Topic 2